{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T10:36:28Z","timestamp":1763116588808},"reference-count":34,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","oooojournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.oooo.2018.05.008","type":"journal-article","created":{"date-parts":[[2018,5,30]],"date-time":"2018-05-30T17:38:31Z","timestamp":1527701911000},"page":"e208-e211","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Chronic myelogenous leukemia presenting with osteonecrosis of the jaw as a rare but debilitating toxicity of dasatinib: a case report and literature review"],"prefix":"10.1016","volume":"126","author":[{"given":"Alexander M.","family":"Won","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prajwal","family":"Boddu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adegbenga O.","family":"Otun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Aponte-Wesson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Chambers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.oooo.2018.05.008_bib0010","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw\u20142014 update","volume":"72","author":"Ruggiero","year":"2014","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.oooo.2018.05.008_bib0015","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic","volume":"61","author":"Marx","year":"2003","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.oooo.2018.05.008_bib0020","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.joms.2004.02.004","article-title":"Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases","volume":"62","author":"Ruggiero","year":"2004","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.oooo.2018.05.008_bib0025","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.oooo.2018.05.008_bib0030","first-page":"1125","article-title":"A double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.oooo.2018.05.008_bib0035","doi-asserted-by":"crossref","first-page":"712","DOI":"10.3111\/13696998.2012.675380","article-title":"Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States","volume":"15","author":"Stopeck","year":"2012","journal-title":"J Med Econ"},{"key":"10.1016\/j.oooo.2018.05.008_bib0040","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3389\/fonc.2014.00146","article-title":"Targeted treatments of bone metastases in patients with lung cancer","volume":"4","author":"Hirsh","year":"2014","journal-title":"Front Oncol"},{"key":"10.1016\/j.oooo.2018.05.008_bib0045","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jbo.2017.09.003","article-title":"The Skeletal-related events of denosumab versus zoledronic acid in patients with bone metastases: a meta-analysis of randomized controlled trials","volume":"9","author":"Zhang","year":"2017","journal-title":"J Bone Oncol"},{"key":"10.1016\/j.oooo.2018.05.008_bib0050","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.joms.2009.10.010","article-title":"Osteonecrosis of the jaw in a patient on denosumab","volume":"68","author":"Aghaloo","year":"2010","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.oooo.2018.05.008_bib0055","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.bjoms.2009.08.030","article-title":"Osteonecrosis of the jaws induced by anti-RANK ligand therapy","volume":"48","author":"Taylor","year":"2010","journal-title":"Br J Oral Maxillofac Surg"},{"key":"10.1016\/j.oooo.2018.05.008_bib0060","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1200\/JCO.2007.15.5424","article-title":"Osteonecrosis of the jaw related to bevacizumab","volume":"26","author":"Estilo","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.oooo.2018.05.008_bib0065","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1093\/annonc\/mdn653","article-title":"Bevacizumab-associated osteonecrosis of the jaw. Bevacizumab-associated osteonecrosis of the jaw","volume":"19","author":"Greuter","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.oooo.2018.05.008_bib0070","author":"US Food and Drug Administration"},{"key":"10.1016\/j.oooo.2018.05.008_bib0075","first-page":"281","article-title":"Dasatinib in chronic myeloid leukemia: a review","volume":"5","author":"Aguilera","year":"2009","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.oooo.2018.05.008_bib0080","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.clml.2013.05.012","article-title":"A critical review of trials of first-line BCR-ABL inhibitor treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase","volume":"13","author":"Jabbour","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.oooo.2018.05.008_bib0085","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1200\/JCO.2007.14.9260","article-title":"Intermittent target inhibition with dasatinib 100\u2009mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia","volume":"26","author":"Shah","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.oooo.2018.05.008_bib0090","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.oooo.2017.10.010","article-title":"Medication related osteonecrosis of the jaws associated with targeted therapy as monotherapy and in combination with antiresorptives. A report of 7 cases from the Copenhagen Cohort","volume":"125","author":"Abel Mahedi Mohamed","year":"2018","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.oooo.2018.05.008_bib0095","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.oooo.2018.05.008_bib0100","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.oooo.2018.05.008_bib0105","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.clml.2017.02.023","article-title":"Elderly patients with chronic myeloid leukemia benefit from a dasatinib dose as low as 20\u2009mg","volume":"17","author":"Itamura","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.oooo.2018.05.008_bib0110","first-page":"270","article-title":"The Src family kinase inhibitor, dasatinib, inhibits angiogenesis in vitro and in vivo","volume":"68","author":"Liang","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.oooo.2018.05.008_bib0115","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1161\/STROKEAHA.109.564229","article-title":"Vascular endothelial growth factor receptor-2 inhibition promotes cell death and limits endothelial cell proliferation in a neonatal rodent model of stroke","volume":"41","author":"Shimotake","year":"2010","journal-title":"Stroke"},{"key":"10.1016\/j.oooo.2018.05.008_bib0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0034914","article-title":"Dasatinib as a bone-modifying agent: anabolic and anti-resorptive effects","volume":"7","author":"Garcia-Gomez","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.oooo.2018.05.008_bib0125","doi-asserted-by":"crossref","first-page":"151","DOI":"10.4103\/0975-5950.127643","article-title":"Bisphosphonates related osteonecrosis of the jaw","volume":"4","author":"Gupta","year":"2013","journal-title":"Natl J Maxillofac Surg"},{"key":"10.1016\/j.oooo.2018.05.008_bib0130","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4137\/CMBD.S24628","article-title":"Dasatinib induced avascular necrosis of femoral head in adult patient with chronic myeloid leukemia","volume":"8","author":"Yassin","year":"2015","journal-title":"Clin Med Insights Blood Disord"},{"key":"10.1016\/j.oooo.2018.05.008_bib0135","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2165\/00003088-200544090-00001","article-title":"Clinical pharmacokinetics of imatinib","volume":"44","author":"Peng","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.oooo.2018.05.008_bib0140","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1053\/j.seminoncol.2011.01.014","article-title":"Pharmacokinetics and pharmacodynamics of nilotinib in gastrointestinal stromal tumors","volume":"38","author":"Trent","year":"2011","journal-title":"Semin Oncol"},{"key":"10.1016\/j.oooo.2018.05.008_bib0145","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s40262-016-0391-6","article-title":"Clinical pharmacokinetics and pharmacodynamics of bosutinib","volume":"55","author":"Abbas","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.oooo.2018.05.008_bib0150","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s00280-017-3240-x","article-title":"Absorption, metabolism, and excretion of [14 C]ponatinib after a single oral dose in humans","volume":"79","author":"Ye","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.oooo.2018.05.008_bib0155","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1038\/bjc.2012.385","article-title":"Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases","volume":"107","author":"Beuselinck","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.oooo.2018.05.008_bib0160","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1016\/j.joms.2013.03.019","article-title":"Combination of zoledronic acid and targeted therapy is active but may induce osteonecrosis of the jaw in patient with metastatic renal cell carcinoma","volume":"7","author":"Smidt-Hansen","year":"2013","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.oooo.2018.05.008_bib0165","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000201931","article-title":"Combination of bis- phosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone","volume":"76","author":"Christodoulou","year":"2009","journal-title":"Oncology"},{"key":"10.1016\/j.oooo.2018.05.008_bib0170","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.clgc.2014.12.002","article-title":"Osteonecrosis of the jaw in patients with metastatic renal cell cancer treated with bisphosphonates and targeted agents: results of an Italian multicenter study and review of the literature","volume":"13","author":"Fusco","year":"2015","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.oooo.2018.05.008_bib0175","doi-asserted-by":"crossref","first-page":"120","DOI":"10.5125\/jkaoms.2017.43.2.120","article-title":"A rare case of osteonecrosis of the jaw related to imatinib","volume":"43","author":"Viviano","year":"2017","journal-title":"J Korean Assoc Oral Maxillofac Surg"}],"container-title":["Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212440318309520?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212440318309520?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T12:23:53Z","timestamp":1540297433000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212440318309520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S2212440318309520"],"URL":"https:\/\/doi.org\/10.1016\/j.oooo.2018.05.008","relation":{},"ISSN":["2212-4403"],"issn-type":[{"value":"2212-4403","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chronic myelogenous leukemia presenting with osteonecrosis of the jaw as a rare but debilitating toxicity of dasatinib: a case report and literature review","name":"articletitle","label":"Article Title"},{"value":"Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oooo.2018.05.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}